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Abstract: The goal of this research was to investigate the potential of newly synthesized 
gold complex trichloro(2,4,6-trimethylpyridine)Au(III) as an anticancer agent. The gold(III) 
complex was synthesized and grafted on nanoporous silica, MCM-41, to produce AuCl3@PF-
MCM-41 (AuCl3 grafted on pyridine-functionalized MCM-41). The toxicity of trichloro(2,4,6-
trimethylpyridine)Au(III) and AuCl3@PF-MCM-41 in Saccharomyces cerevisiae (as a model 
system) was studied. The gold(III) complex showed a mid cytotoxic effect on yeast viability. 
Using the drug delivery system, nanoporous MCM-41, the gold(III) complex became a strong 
inhibitor for growth of yeast cells at a very low concentration. Furthermore, the animal tests 
revealed a high uptake of AuCl3@PF-MCM-41 in tumor cells. The stability of the compound 
was confirmed in human serum.
Keywords: trichloro(2,4,6-trimethylpyridine)Au(III), MCM-41, Au(III), Saccharomyces 
cerevisiae, anticancer agent
Introduction
The strong anticancer effects of cisplatin demonstrated that other metal-based 
  compounds might have the potential to act as anticancer agents.1,2 The isoelectronic and 
isostructural with Pt(II); Au(III), is a suitable candidate to defeat cancer cells. While 
Au(III) analogs will easily reduce to metallic gold under physiological conditions,3 
in the early 1990s, a few gold compounds were prepared and characterized for their 
antitumor activity with positive results.4,5 Recently, using various Au(III) complexes 
with novel functionality has elicited more interest due to their distinct physical and 
chemical properties, stability under physiological conditions, and outstanding   cytotoxic 
effects.6,7
The toxicity of gold complexes originates from two aspects: interactions with 
the negatively charged cell and subcellular membranes; and from the fact that 
trapped particles in vesicles are able to disrupt the membrane.8 Using endocytotic 
mechanisms most of the nanoparticle bioconjugates enter the cells in a manner 
dependent on size and shape.9–13 Following the absorption, these nanoparticles 
need to reach their subcellular targets to be effective. To increase the efficiency of 
uptake and prevent aggregation, the gold complexes can be loaded on a drug deliv-
ery system.11
The potential of pyridine-Au(I) compounds for practical application has 
recently been demonstrated.14 Spasmolytic, diuretic, anticoagulant, anticancer, and 
antianaphylactic activities of pyrans were reported.15–17 Moreover, the antitumor International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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activities of a series of pyridine, pyrane, and pyrimidine 
derivatives have been evaluated on 59 different human tumor 
cell lines. Some of the pyridine-based compounds are highly 
selective and inhibit leukemia cell lines.18
In this study, 2,4,6-trimethylpyridine was reacted with 
HAuCl4 to produce trichloro(2,4,6-trimethylpyridine)
Au(III) complex. To provide an efficient amount of 
trichloro(2,4,6-trimethylpyridine)Au(III) inside the cells, 
the complex was loaded on a nanoporous MCM-41 drug 
delivery system. Nanoporous MCM-41 is absorbed effi-
ciently by various mammalian cells.13,19 The nanoporous 
silica features a high surface area (1064 m2/g), large pore 
volume (0.9 mL/g), tunable pore size (2–10 nm), and good 
chemical stability.13,19 In addition, the biocompatibility of 
nanoporous MCM-41 with and without surface function-
alization has been assayed in different procedures.6 The 
authors have previously introduced nanoporous MCM-41 
as an acceptable host for grafting of complexes with opti-
cal properties.19
Saccharomyces cerevisiae was used to test the toxicity 
of trichloro(2,4,6-trimethylpyridine)Au(III) in vivo. It is an 
excellent model system to investigate mechanisms of drug 
resistance and toxicity. Most of the human enzymatic and 
cellular structures, the oxidative stress response, and the 
family of drug resistance pumps are also present in yeast.20 
As well as biodistribution and stability, analyses were per-
formed in five Sprague Dawley® rats bearing breast tumor 
and human serum.
Materials and methods
Materials
All chemicals were purchased either from Sigma-Aldrich® 
(St Louis, MO) or Merck Chemicals (Darmstadt, Germany) 
and used without further purification. All reactions and 
manipulations were carried out in an atmosphere of dry 
nitrogen, using standard Schlenk techniques. Solvents were 
dried and distilled under nitrogen prior to use, according to 
standard procedures. Nanoporous MCM-41 was synthesized, 
as previously reported.21 Infrared spectra were recorded 
(KBr pellets) on a Shimadzu FTIR 4600  spectrometer 
(Kyoto, Japan). The elemental analyses (carbon hydrogen 
nitrogen [CHN]) were performed on a Thermo Finnigan 
Flash EA™ 1112 microanalyzer (San Jose, CA). All 
samples were dried in an atmosphere of dry nitrogen, using 
standard Schlenk   techniques before analysis at 300°C for 
3 hours.   Low-angle X-ray diffraction (XRD) patterns were 
obtained on a Philips Analytical PW-17C diffractometer 
(Eindhoven, The Netherlands) with Cu Kα radiation. 
Scans were performed from (2θ) 1° to 10° at a rate of 3°/
minute. Thermal analysis was carried out on a Rheometric 
  Scientific Simultaneous Thermal Analyzer 1500 (Leather-
head, Surrey, UK) with a heating rate of 10°C/minute in air. 
The photoluminescence spectra were carried out using the 
second (532 nm)   harmonic of a Ocean Optic USB2000-FLG 
spectrofluorometer (Dunedin, FL) with Nd:YAG laser for 
excitation.
synthesis
Preparation of trichloro(2,4,6-trimethylpyridine)
Au(III)
Two millimole of 2,4,6-trimethylpyridine in 10 mL methanol 
was added to 2 mM (0.80 g) of HAuCl4.3H2O in 10 mL of 
acetonitrile. The resulting deep yellow solution was stirred at 
40°C for 30 minutes followed by filtration. In about 7 days, 
yellow crystals appeared by simple evaporation. Infrared 
(KBr Disk, cm-1): 3433 s, 3054 w, 2922 w, 2843 w, 1623 m, 
1545 m,1464 m, 1401 w, 1368 m, 1309 w, 1246 w, 1034 m, 
936 w, 857 m, 704 m, 536 w, 463 w. Ultraviolet-visible spec-
trometry: 217, 265, and melting point .573°C.
Preparation of Aucl3@PF-McM-41
Preparation of pyridine-functionalized McM-41 
(PF-McM-4)
Eight millimole 4-methylpyridine in tetrahydrofuran (THF) 
was mixed with one equivalent of lithium diisopropylamine 
in a total volume of 80 mL THF at 40°C for 2 hours 
 ( Figure 1). The yielded brown solution was chilled (20°C), 
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Figure 1 schematic procedure of grafting Au(III) complex on pyridine-functionalized McM-41.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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treated with 2.0 g MCM-41-grafted chloropropylsilyl groups, 
and stirred for 72 hours at 4°C. The pale pellet was washed 
three times with absolute ethanol and diethyl ether followed 
by drying in 1 mmHg at room temperature for 48 hours.   
A pyridine loading of 0.2 mM g-1 was obtained for PF-MCM-41 
as found by carbon and nitrogen analysis (CHN: C, 2.05;   
H, 0.30; N, 0.27).22
grafting of hAucl4 on PF-McM-41
One gram of fresh dried PF-MCM-41 was treated with 
equivalent mole of HAuCl4 · 3H2O (0.2 mM, 0.08 g in 10 mL 
acetonitrile) in a medium of 25 mL dried methanol. The pale 
rose suspension was stirred for 5 hours then washed   copiously 
with water. After filtration and drying under vacuum at 
room temperature for 3 hours, the AuCl3@PF-MCM-41 
was obtained.
cytotoxicity test in yeast cells
To test the biological properties of trichloro(2,4,6-trimeth-
ylpyridine)Au(III), a MATa type of S. cerevisiae was used. 
A 48-hour colony of this yeast was grown in 1% yeast 
extracts, 2% meat peptone, and 2% dextrose (here, glucose) 
(YPD)23 for 16 hours at 30°C. A cell density of OD600 0.05 was 
inoculated in 100 mL fresh YPD media for 2 hours (30°C and 
200 rpm) to have the cells at a logarithmic phase of growth. 
An initial cell density of OD600 0.01 from the 2-hour-old 
culture was supplemented with 0, 5, 7, 10, 15, 20, 22, and 
25 mM of the trichloro(2,4,6-trimethylpyridine)Au(III), 0, 
0.15, 0.25, 0.5, 1, 2, 3, 5, 10, 20, and 25 mM AuCl3@PF-
MCM-41, and 0, 0.1, 0.5, 1, 5, and 10 mM MCM-41. All 
treatments were incubated at 30°C in a rotary shaker with 
200 rpm for 24 hours. The OD600 of the cells was measured 
12 times at 2-hour intervals and in three independent repeats. 
The resulting growth curve represented the average optical 
density of the yeast cells. The IC50 (half-maximal inhibitory 
concentration) for trichloro(2,4,6-trimethylpyridine)Au(III) 
and AuCl3@PF-MCM-41 was calculated based on their 
growth rates.
Biodistribution and stability analyses
Animal assays were performed in accordance with the United 
Kingdom Biological Council’s Guidelines on the Use of 
Living Animals in Scientific Investigations.24 Five Sprague 
Dawley rats (8–10 weeks of age; average body weight 
320 ± 5 g) bearing breast tumor received 25 mg/kg AuCl3@
PF-MCM-41, or equal volume of double distilled water, to 
control counterparts via tail vein injection. The rats were 
maintained at 22°C–24°C with a 12-hour light:dark cycle, 
and were provided with drinking water and fed ad libitum 
for 24 hours. The animals were sacrificed by CO2 asphyxi-
ation followed by excising the tumor and taking blood for 
comparative analyses. Tumors were weighed, rinsed in a 
normal saline buffer, and crushed in liquid nitrogen. Serums 
were prepared from centrifugation of coagulated blood. The 
aqua from tumor cells and serums were assayed for emission 
standard peak of AuCl3@PF-MCM-41.
In vitro stability test
Serum samples were incubated with 2 mM of AuCl3@PF-
MCM-41 at 37°C in shaker incubators (100 rpm) for 24 and 
48 hours. The infrared (IR) analyses were carried out for 
AuCl3@PF-MCM-41, as described above.
Results
A new complex of gold(III), trichloro(2,4,6-trimethyl 
-pyridine)Au(III), was synthesized and analyzed for 
  chemical structure. To provide enough of the complex 
inside cells, nanoporous MCM-41 drug delivery system 
was used to produce AuCl3@PF-MCM-41. Cytotoxicity 
of trichloro(2,4,6-trimethylpyridine)Au(III) and AuCl3@
PF-MCM-41 were studied in S. cerevisiae. Biodiversity 
and stability of AuCl3@PF-MCM-41 were evaluated in rats 
bearing breast tumor and human serums.
synthesis of (2,4,6-trimethylpyridine)
Au(III) complex
The title complex was prepared by reacting HAuCl4 · 3H2O 
to corresponding ligand (1:1 equivalent ratio) in a mixture 
of methanol and acetonitrile at 40°C. The progress of the 
reaction was followed by the appearance of a very intense yel-
low fluorescence. The massive crystallization of the product 
in a form of plate crystals occurred after about 7 days at 30°C. 
Pyridine and its derivatives coordinated directly to the gold 
center in a square planer form, and neither hydrogen transfer 
nor polymerization occurred.25–27 Presence of the gold(III) 
complex on MCM-41 was confirmed using IR and CHN.
Photoluminescence measurements  
and absorption spectrum
The photoluminescence properties of the gold(III) complex 
were measured in aqueous solution. As previously reported,28 
in all cases the luminescent excited states were apparently 
intraligand triplets (436.93, 465.4, and 496.87 nm). 
Attachment of an electron withdrawing nitrogen substituent 
to the aromatic ring with three electron donors methyl groups 
resulted in blue-shifted emission with respect to pyridine29 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and confirmed formation of trichloro(2,4,6-trimethyl- 
pyridine)Au(III) complex.
Au(III) with d8 electronic configuration adopts an 
assortment of square-planar geometry, which leads to ligand 
field transitions.30 Au(III) center is an oxidized   species, 
therefore, low-energy ligand to metal charge transfer (LMCT) 
transitions are quite common in contrast to metal to ligand 
charge transfer (MLCT) transitions.
XrD patterns
Figure 2 illustrates the low angle XRD patterns of PF-
MCM-41 and AuCl3@PF-MCM-41. The cell parameters 
(a0 = 2d100/√3) of 4.18 and 4.10 nm, were calculated for 
PF-MCM-41 and AuCl3@PF-MCM-41, respectively. Both 
patterns exhibit a high-intensity (100) reflection within 2θ in 
the range of 2°–3°. The similar d100 spacing values indicated 
that the two-dimensional hexagonal nanoporous structures 
(P6 mm) of MCM-41 were maintained after introducing the 
gold(III) complex.31 In comparison with MCM-41 diffrac-
tion, intensity of the grafted materials decreased significantly 
(a0 = 4.36 nm); this, along with the decrease in surface areas 
(in situ), showed that the nanoporous channels were occupied 
by the gold complex.
Toxicity test in vivo
The 24-hour growth curves of S. cerevisiae were   generated 
in liquid YPD supplemented with a different amount of 
trichloro(2,4,6-trimethylpyridine)Au(III), AuCl3@PF-
MCM-41, and nanoporous MCM-41 as a control. The 
results are presented in Figures 3–6. Logical decreases 
were observed in the growth rate of yeast cells treated 
with 5–25 mM trichloro(2,4,6-trimethylpyridine)Au(III) 
(Figure 3). Lower amounts of the complex (5 and 7 mM) 
revealed almost no toxic effect on the treated cells (Figure 4), 
while higher concentrations up to 15 mM obviously limited 
the growth rate (Figure 5). Twenty to twenty-five millimolar 
of trichloro(2,4,6-trimethylpyridine)Au(III) fully inhibited 
growth of yeast (Figure 6). The IC50 for trichloro(2,4,6-
trimethylpyridine)Au(III) was about 12 mM.
Yeast cells showed growth inhibition at AuCl3@PF-
MCM-41 concentration of 1 mM and higher where they 
tolerated 15 mM trichloro(2,4,6-trimethylpyridine)Au(III) 
(Figure 5). As is shown in Figure 4, yeast tolerated 0.15 and 
0.25 mM of AuCl3@PF-MCM-41. Cells behaved nearly the 
same under treatment of 20–25 mM AuCl3@PF-MCM-41 
and trichloro(2,4,6-trimethylpyridine)Au(III) (Figure 6). 
The IC50 for AuCl3@PF-MCM-41 dropped about 50 times 
to nearly 0.25 mM in comparison with trichloro(2,4,6-
trimethylpyridine)Au(III) (Figures 4 and 5).
The presence of different amount of nanoporous MCM-41 
had no toxic effects on yeast growth (Figures 4–6).
Biodistribution and stability analyses
AuCl3@PF-MCM-41 was well tolerated in rats at a dose 
of 25 mg/kg. In comparison to the control group, no 
abnormalities in feeding and other behaviors were observed. 
Biodistribution studies revealed a higher tumor uptake within 
24 hours compared to the blood tissue. The average tumor 
uptake was 3.8 to that of blood (mMol/mMol).
To investigate in vitro stability of AuCl3@PF-MCM-41, 
the treated human blood serums were analyzed with IR. The 
results confirmed stability of AuCl3@PF-MCM-41 in human 
serum within 24 and 48 hours.
Discussion
To maximize the toxic effects of gold(III) on cells, a new 
  complex of gold(III), trichloro(2,4,6-trimethylpyridine)
Au(III), was synthesized and grafted on nanoporous 
MCM-41. Its toxicity in S. cerevisiae, biodiversity in rat 
bearing breast tumor, and stability in human serum was 
evaluated in this study.
Trichloro(2,4,6-trimethylpyridine)Au(III) complex did 
not inhibit yeast growth as previously reported for   HAuCl4.32 
One and a half millimolar HAuCl4 · 3H2O completely 
retarded the growth of yeast cells,32 whereas trichloro(2,4,6- 
trimethylpyridine)Au(III) at a similar concentration of 
gold had no toxic effect on the cells. The differentiation in 
toxicity of these materials most likely originates from their 
interactions with the negatively charged cell membranes. 
Based on the results reported by De la Fuente et al,11 the 
  aggregation of trichloro(2,4,6-trimethylpyridine)Au(III) 
under physiological conditions may lead to fewer inhibitory 
effects than HAuCl4 on yeast cells.
To identify whether a drug delivery system changes the 
toxicity of trichloro(2,4,6-trimethylpyridine)Au(III), the 
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Figure 2 X-ray diffraction patterns of PF-McM-41 (A) and Aucl3@PF-McM-41 (B).   
The patterns exhibit a high intensity (100) reflection within the 2θ range of 2°–3°. 
The  similar  d100  spacing  values  confirmed  the  maintenance  of  two-dimensional 
hexagonal mesoporous structures (P6 mm) of McM-41 after introducing complexes.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 growth inhibition of yeast cells by adding the indicated amounts of trichloro(2,4,6-trimethylpyridine)Au(III). Using 5–25 mM trichloro(2,4,6-trimethylpyridine)
Au(III) logical decreases were observed in growth rate.
Abbreviation: Tc(2,4,6TMP)gold(III), trichloro(2,4,6-trimethylpyridine)Au(III).
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0.1 mM MCM-41
0.5 mM MCM-41
5 mM TC(2,4,6TMP)gold(III)
7 mM TC(2,4,6TMP)gold(III)
10 mM TC(2,4,6TMP)gold(III)
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Figure 4 growth curves of yeast cells by adding the low amounts of McM-41, trichloro(2,4,6-trimethylpyridine)Au(III), Aucl3@PF-McM-41. 5 and 7 mM of Tc(2,4,6TMP)
gold(III) showed no toxic effect on the treated cells while 0.15 mM Aucl3@PF-McM-41 limited growth rate of the cells stronger than 10 mM Tc(2,4,6TMP)gold(III).
Abbreviation: Tc(2,4,6TMP)gold(III), trichloro(2,4,6-trimethylpyridine)Au(III).
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5 mM MCM-41
10 mM TC(2,4,6TMP)gold(III)
15 mM TC(2,4,6TMP)gold(III)
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Figure 5 growth curves of yeast cells by adding the moderate amounts of McM-41, trichloro(2,4,6-trimethylpyridine)Au(III) and Aucl3@PF-McM-41. The cells grew about 
control in YPD media under the condition of 5 mM McM-41. Up to 15 mM Tc(2,4,6TMP)gold(III) was tolerated. 1 mM was growth rate inhibition threshold for Aucl3@
PF-McM-41.
Abbreviation: Tc(2,4,6TMP)gold(III), trichloro(2,4,6-trimethylpyridine)Au(III).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Au(III) complex was grafted on MCM-41 to produce AuCl3@
PF-MCM-41. MCM-41, with pore size of 10–60 nm, are 
uptaken by mammalian, yeast, and bacteria cells through 
the endocytosis mechanism.13 No cytotoxicity effects have 
been shown by introducing nanoporous MCM-41 to cells.13 
In this study, the growth curves for yeast at a MCM-41 
  concentration of 0.1, 0.5, 5, and 10 mM confirmed this 
evidence (Figures 4–6). Although, the OD600 nm of the cell 
suspensions treated with 0.15 mM AuCl3@PF-MCM-41 
depleted to a maximum of 0.7. Yeast cells were hypersensitive 
to 0.5 mM AuCl3@PF-MCM-41 but not susceptible to 5 and 
7 mM trichloro(2,4,6-trimethylpyridine)Au(III) (Figure 4), 
suggesting that the nanoporous MCM-41 makes the gold(III) 
complex a strong cell killing agent.
Conclusion
The combined results of this study show that the grafting 
of 0.2 mM trichloro(2,4,6-trimethylpyridine)Au(III) on 
1.0 g MCM-41 dropped the IC50 about 50-fold to the IC50 of 
0.25 mM. These data, in comparison with those from HAuCl4 
complex,32 reveal the toxic effects of trichloro(2,4,6-trimethyl
pyridine)Au(III) on S. cerevisiae. In addition, they confirm the 
role of nanoporous MCM-41 in delivery of the gold(III) com-
plex to their target(s) in cells. The tested complexes were toxic 
to the cells as MCM-41 , trichloro(2,4,6-  trimethylpyridine)
Au(III) , AuCl3@PF-MCM-41. These results also confirmed 
zero premature release of trichloro(2,4,6-trimethylpyridine)
Au(III). The toxicity of AuCl3@PF-MCM-41 on yeast cells 
comes from guaranteed transferring, preventing aggregation, 
and most probably reaching target biomolecules of the gold 
complex. Furthermore, the   preliminary animal tests featured 
relatively good tumor uptake without utilizing a selective 
tumor delivery system (tumor to blood uptake ratio = 3.8). 
The stability test in human serum, showed that Au(III) moiety 
stabilized significantly at neutral pH through an appropriate 
choice of ligand and interface ligand on nanoporous silica 
while preserving its chemical and biological properties.
Without any experimental evidence for subcellular 
localization of and drug release from AuCl3@PF-MCM-41, 
it is thought that the mode of action is dependent on free 
AuCl3@PF-MCM-41 in cytosol or most probably in the 
nucleus. The high cytotoxic effects of AuCl3@PF-MCM-41, 
low cytotoxicity of trichloro(2,4,6-trimethylpyridine)Au(III) 
(Figures 5 and 6) in case of undesired release under physio-
logical conditions, and the stability of AuCl3@PF-MCM-41 in 
serum all suggest the potential of trichloro(2,4,6-trimeth-
ylpyridine)Au(III) as a cell killer for cancer therapy.
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